<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">porozendo</journal-id><journal-title-group><journal-title xml:lang="ru">Остеопороз и остеопатии</journal-title><trans-title-group xml:lang="en"><trans-title>Osteoporosis and Bone Diseases</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-2680</issn><issn pub-type="epub">2311-0716</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/osteo9733</article-id><article-id custom-type="elpub" pub-id-type="custom">porozendo-9733</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Клинический случай (или краткое сообщение)</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Case report</subject></subj-group></article-categories><title-group><article-title>Несовершенный остеогенез как причина летального исхода</article-title><trans-title-group xml:lang="en"><trans-title>Osteogenesis imperfecta as a cause of death</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4567-2412</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Малыгина</surname><given-names>Анастасия Андреевна</given-names></name><name name-style="western" xml:lang="en"><surname>Malygina</surname><given-names>Anastasia A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>научный сотрудник отделения нейроэндокринологии и остеопатий ФГБУ НМИЦ Эндокринологии МЗ РФ</p></bio><email xlink:type="simple">malygina.aa@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1413-1549</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гребенникова</surname><given-names>Татьяна Алексеевна</given-names></name><name name-style="western" xml:lang="en"><surname>Grebennikova</surname><given-names>Tatiana A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>научный сотрудник отделения нейроэндокринологии и остеопатий, к.м.н.</p></bio><bio xml:lang="en"><p>MD, PhD</p></bio><email xlink:type="simple">grebennikova@hotmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8500-4841</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тюльпаков</surname><given-names>Анатолий Николаевич</given-names></name><name name-style="western" xml:lang="en"><surname>Tiulpakov</surname><given-names>Anatoly N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>зав. отделения наследственных эндокринопатий детского возраста, д.м.н., профессор</p></bio><bio xml:lang="en"><p>MD, PhD</p></bio><email xlink:type="simple">anatolytiulpakov@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6674-6441</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белая</surname><given-names>Жанна Евгеньевна</given-names></name><name name-style="western" xml:lang="en"><surname>Belaya</surname><given-names>Zhanna E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>зав.отделением нейроэндокринологии и остеопатий, д.м.н., профессор</p></bio><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><email xlink:type="simple">jannabelaya@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>&lt;p&gt;ФГБУ &amp;laquo;Национальный медицинский исследовательский центр эндокринологии&amp;raquo; Минздрава России&lt;/p&gt;</institution><country>Россия</country></aff><aff xml:lang="en"><institution>&lt;p&gt;Endocrynology Research Centre&lt;/p&gt;</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>25</day><month>04</month><year>2018</year></pub-date><volume>21</volume><issue>1</issue><fpage>23</fpage><lpage>27</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Малыгина А.А., Гребенникова Т.А., Тюльпаков А.Н., Белая Ж.Е., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Малыгина А.А., Гребенникова Т.А., Тюльпаков А.Н., Белая Ж.Е.</copyright-holder><copyright-holder xml:lang="en">Malygina A.A., Grebennikova T.A., Tiulpakov A.N., Belaya Z.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.osteo-endojournals.ru/jour/article/view/9733">https://www.osteo-endojournals.ru/jour/article/view/9733</self-uri><abstract><p>Несовершенный остеогенез (НО) представляет собой редкое генетическое заболевание соединительной ткани, вызванное в подавляющем большинстве случаев мутациями в генах COL1A1 и COL1A2, ответственных за синтез коллагена 1 типа, которое приводит к развитию множественных переломов костей и прогрессирующим деформациям скелета из-за дефицита коллагена I типа. Известно 15 типов НО, из которых наиболее тяжелым течением отличается II тип НО в виду 100% смертности больных в неонатальном или перинатальном периодах. Структура смертности при других типах НО мало изучена в виду гетерогенности клинической симптоматики и тяжести поражения соединительной ткани. В статье приводится описание клинического случая НО III типа, осложненного генерализованным остеопорозом с множественными переломами тел позвонков и трубчатых костей и выраженным кифосколиозом, обусловившим летальный исход.</p></abstract><trans-abstract xml:lang="en"><p>Osteogenesis imperfecta (OI) is a rare heterozygous connective tissue disordercaused by mutations in genes that affect collagen components (in most cases mutations in COL1A1 и COL1A2 genes). The current classification system includes 15 types of OI, one of which (type II) is characterized by 100% intrauterine or perinatal mortality. The structure of mortality in other OI types is poorly understood because of the heterogeneity of clinical symptoms and the severity of connective tissue damage. W present a clinical case of type III osteogenesis imperfecta, complicated by generalized osteoporosis with multiple fractures of vertebrae and tubular bones and progressive kyphoscoliosis. Late-initiated treatment led to progression of the disease and led to cardiopulmonary insufficiency and death of the patient. Our clinical case highlights the importance of timely diagnosis, treatment and regular observation in patients with OI.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>несовершенный остеогенез</kwd><kwd>остеопороз</kwd><kwd>смертность</kwd><kwd>бисфосфонаты</kwd><kwd>Деносумаб</kwd><kwd>клинический случай</kwd></kwd-group><kwd-group xml:lang="en"><kwd>osteoporosis</kwd><kwd>bone fracture</kwd><kwd>denosumab</kwd><kwd>bisphosphonates</kwd><kwd>expert opinion</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Cole W. Advances in Osteogenesis Imperfecta. Clin Orthop Relat Res. 2002;401:6-16. doi: 10.1097/00003086-200208000-00003</mixed-citation><mixed-citation xml:lang="en">Cole W. Advances in Osteogenesis Imperfecta. Clin Orthop Relat Res. 2002;401:6-16. doi: 10.1097/00003086-200208000-00003</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Cole W. The Nicholas Andry Award-1996 The Molecular Pathology of Osteogenesis Imperfecta. Clin Orthop Relat Res. 1997;343:235-248. doi: 10.1097/00003086-199710000-00034</mixed-citation><mixed-citation xml:lang="en">Cole W. The Nicholas Andry Award-1996 The Molecular Pathology of Osteogenesis Imperfecta. Clin Orthop Relat Res. 1997;343:235-248. doi: 10.1097/00003086-199710000-00034</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Brusin JH. Osteogenesis imperfecta. Radiol Technol. 2008;79(6):535–548.</mixed-citation><mixed-citation xml:lang="en">Brusin JH. Osteogenesis imperfecta. Radiol Technol. 2008;79(6):535–548.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Gonnelli S, Caffarelli C, Giordano N, Nuti R. The prevention of fragility fractures in diabetic patients. Aging Clin Exp Res. 2014;27(2):115-124. doi: 10.1007/s40520-014-0258-3</mixed-citation><mixed-citation xml:lang="en">Gonnelli S, Caffarelli C, Giordano N, Nuti R. The prevention of fragility fractures in diabetic patients. Aging Clin Exp Res. 2014;27(2):115-124. doi: 10.1007/s40520-014-0258-3</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Steiner R, Adsit J, Basel D. COL1A1/2-Related Osteogenesis Imperfecta. Ncbinlmnihgov. 2018. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1295/. Accessed June 22, 2018.</mixed-citation><mixed-citation xml:lang="en">Steiner R, Adsit J, Basel D. COL1A1/2-Related Osteogenesis Imperfecta. Ncbinlmnihgov. 2018. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1295/. Accessed June 22, 2018.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Sillence D, Rimoin D. Classification of osteogenesis imperfecta. The Lancet. 1978;311(8072):1041-1042. doi:10.1016/s0140-6736(78)90763-8</mixed-citation><mixed-citation xml:lang="en">Sillence D, Rimoin D. Classification of osteogenesis imperfecta. The Lancet. 1978;311(8072):1041-1042. doi:10.1016/s0140-6736(78)90763-8</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Белова Н.А., Костик М.М., Буклаев Д.С., и др. Федеральные клинические рекомендации (протокол) по оказанию медицинской помощи пациентам с несовершенным остеогенезом. — М., 2015. Доступно по http://мороздгкб.рф/wp-content/uploads/2017/03/Федеральные-клинические-рекомендации-протокол-по-оказанию-медицинской-помощи-пациентам-с-несовершенным-остеогенезом.pdf [Belova NА, Kostik MM, Buklaev DS, et al. Federal'nye klinicheskie rekomendatsii (protokol) po okazaniyu meditsinskoj pomoshhi patsientam s nesovershennym osteogenezom. — Moscow; 2015. Available at: http://мороздгкб.рф/wp-content/uploads/2017/03/Федеральные-клинические-рекомендации-протокол-по-оказанию-медицинской-помощи-пациентам-с-несовершенным-остеогенезом.pdf. (In Russ).]</mixed-citation><mixed-citation xml:lang="en">Белова Н.А., Костик М.М., Буклаев Д.С., и др. Федеральные клинические рекомендации (протокол) по оказанию медицинской помощи пациентам с несовершенным остеогенезом. — М., 2015. Доступно по http://мороздгкб.рф/wp-content/uploads/2017/03/Федеральные-клинические-рекомендации-протокол-по-оказанию-медицинской-помощи-пациентам-с-несовершенным-остеогенезом.pdf [Belova NА, Kostik MM, Buklaev DS, et al. Federal'nye klinicheskie rekomendatsii (protokol) po okazaniyu meditsinskoj pomoshhi patsientam s nesovershennym osteogenezom. — Moscow; 2015. Available at: http://мороздгкб.рф/wp-content/uploads/2017/03/Федеральные-клинические-рекомендации-протокол-по-оказанию-медицинской-помощи-пациентам-с-несовершенным-остеогенезом.pdf. (In Russ).]</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Glorieux FH. Osteogenesis imperfecta. Best Pract Res Clin Rheumatol. 2008;22(1):85–100.</mixed-citation><mixed-citation xml:lang="en">Glorieux FH. Osteogenesis imperfecta. Best Pract Res Clin Rheumatol. 2008;22(1):85–100.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Eddeine H, Dafer R, Schneck M, Biller J. Bilateral Subdural Hematomas in an Adult with Osteogenesis Imperfecta. Journal of Stroke and Cerebrovascular Diseases. 2009;18(4):313-315. doi: 10.1016/j.jstrokecerebrovasdis.2008.11.008</mixed-citation><mixed-citation xml:lang="en">Eddeine H, Dafer R, Schneck M, Biller J. Bilateral Subdural Hematomas in an Adult with Osteogenesis Imperfecta. Journal of Stroke and Cerebrovascular Diseases. 2009;18(4):313-315. doi: 10.1016/j.jstrokecerebrovasdis.2008.11.008</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Khandanpour N, Connolly D, Raghavan A, Griffiths P, Hoggard N. Craniospinal Abnormalities and Neurologic Complications of Osteogenesis Imperfecta: Imaging Overview. RadioGraphics. 2012;32(7):2101-2112. doi: 10.1148/rg.327125716</mixed-citation><mixed-citation xml:lang="en">Khandanpour N, Connolly D, Raghavan A, Griffiths P, Hoggard N. Craniospinal Abnormalities and Neurologic Complications of Osteogenesis Imperfecta: Imaging Overview. RadioGraphics. 2012;32(7):2101-2112. doi: 10.1148/rg.327125716</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">van Dijk F, Cobben J, Kariminejad A et al. Osteogenesis Imperfecta: A Review with Clinical Examples. Mol Syndromol. 2011. doi: 10.1159/000332228</mixed-citation><mixed-citation xml:lang="en">van Dijk F, Cobben J, Kariminejad A et al. Osteogenesis Imperfecta: A Review with Clinical Examples. Mol Syndromol. 2011. doi: 10.1159/000332228</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">McAllion S, Paterson C. Causes of death in osteogenesis imperfecta. J Clin Pathol. 1996;49(8):627-630. doi: 10.1136/jcp.49.8.627</mixed-citation><mixed-citation xml:lang="en">McAllion S, Paterson C. Causes of death in osteogenesis imperfecta. J Clin Pathol. 1996;49(8):627-630. doi: 10.1136/jcp.49.8.627</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Singer RB1, Ogston SA, Paterson CR. Mortality in various types of osteogenesis imperfecta. J Insur Med. 2001;33(3):216-20.</mixed-citation><mixed-citation xml:lang="en">Singer RB1, Ogston SA, Paterson CR. Mortality in various types of osteogenesis imperfecta. J Insur Med. 2001;33(3):216-20.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Folkestad L, Hald J, Canudas-Romo V et al. Mortality and Causes of Death in Patients With Osteogenesis Imperfecta: A Register-Based Nationwide Cohort Study. Journal of Bone and Mineral Research. 2016;31(12):2159-2166. doi: 10.1002/jbmr.2895</mixed-citation><mixed-citation xml:lang="en">Folkestad L, Hald J, Canudas-Romo V et al. Mortality and Causes of Death in Patients With Osteogenesis Imperfecta: A Register-Based Nationwide Cohort Study. Journal of Bone and Mineral Research. 2016;31(12):2159-2166. doi: 10.1002/jbmr.2895</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Белая Ж.Е., Рожинская Л.Я. Бисфосфонаты: мифы и реальность // Эффективная фармакотерапия. - 2010. – №38. - С. 52-59. [Belaya ZE, Rozhinskaya LY. Bisfosfonaty: mify i real'nost'. Effective Pharmacotherapy. 2010;(38);52-59. (In Russ).]</mixed-citation><mixed-citation xml:lang="en">Белая Ж.Е., Рожинская Л.Я. Бисфосфонаты: мифы и реальность // Эффективная фармакотерапия. - 2010. – №38. - С. 52-59. [Belaya ZE, Rozhinskaya LY. Bisfosfonaty: mify i real'nost'. Effective Pharmacotherapy. 2010;(38);52-59. (In Russ).]</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Dwan K, Phillipi CA, Steiner RD, et al. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2016;10:CD005088. DOI: 10.1002/14651858.CD005088.pub4</mixed-citation><mixed-citation xml:lang="en">Dwan K, Phillipi CA, Steiner RD, et al. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2016;10:CD005088. DOI: 10.1002/14651858.CD005088.pub4</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Bregou B, Aubry-Rozier B, Bonafé L, Laurent-Applegate L, Pioletti D, Zambelli P. Osteogenesis imperfecta: from diagnosis and multidisciplinary treatment to future perspectives. Swiss Med Wkly. 2016. doi:10.4414/smw.2016.14322</mixed-citation><mixed-citation xml:lang="en">Bregou B, Aubry-Rozier B, Bonafé L, Laurent-Applegate L, Pioletti D, Zambelli P. Osteogenesis imperfecta: from diagnosis and multidisciplinary treatment to future perspectives. Swiss Med Wkly. 2016. doi:10.4414/smw.2016.14322</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Белая Ж.Е., Рожинская Л.Я. Анаболическая терапия остеопороза. Терипаратид: эффективность, безопасность и область применения. // Остеопороз и остеопатии. - 2013. - Т. 16. - №2. - C. 32-40. [Anabolicheskaya terapiya osteoporoza. Teriparatid: ehffektivnost', bezopasnost' i oblast' primeneniya. Osteoporosis and Bone Diseases. 2013;16(2);32-40 (In Russ).] doi: 10.14341/osteo2013232-40</mixed-citation><mixed-citation xml:lang="en">Белая Ж.Е., Рожинская Л.Я. Анаболическая терапия остеопороза. Терипаратид: эффективность, безопасность и область применения. // Остеопороз и остеопатии. - 2013. - Т. 16. - №2. - C. 32-40. [Anabolicheskaya terapiya osteoporoza. Teriparatid: ehffektivnost', bezopasnost' i oblast' primeneniya. Osteoporosis and Bone Diseases. 2013;16(2);32-40 (In Russ).] doi: 10.14341/osteo2013232-40</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Gatti D, Rossini M, Viapiana O, et al. Teriparatide treatment in adult patients with osteogenesis imperfecta type I. Calcif Tissue Int. 2013;93(5):448–52. doi: 10.1007/s00223-013-9770-2</mixed-citation><mixed-citation xml:lang="en">Gatti D, Rossini M, Viapiana O, et al. Teriparatide treatment in adult patients with osteogenesis imperfecta type I. Calcif Tissue Int. 2013;93(5):448–52. doi: 10.1007/s00223-013-9770-2</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Orwoll ES, Shapiro J, Veith S, et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest. 2014;124(2):491–8. doi: 10.1172/JCI71101</mixed-citation><mixed-citation xml:lang="en">Orwoll ES, Shapiro J, Veith S, et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest. 2014;124(2):491–8. doi: 10.1172/JCI71101</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Белая Ж.Е., Рожинская Л.Я. Новые направления в терапии остеопороза – применение моноклональных человеческих антител к RANKL (Деносумаб) // Остеопороз и остеопатии. - 2011. - Т. 14. - №2. - C. 23-26. [Belaya ZhE, Rozhinskaya LYa. Novye napravleniya v terapii osteoporoza – primenenie monoklonal'nyh chelovecheskih antitel k RANKL (Denosumab). Osteoporosis and Bone Diseases. 2011;14(2):23-26. (In Russ).] doi: 10.14341/osteo2011223-26</mixed-citation><mixed-citation xml:lang="en">Белая Ж.Е., Рожинская Л.Я. Новые направления в терапии остеопороза – применение моноклональных человеческих антител к RANKL (Деносумаб) // Остеопороз и остеопатии. - 2011. - Т. 14. - №2. - C. 23-26. [Belaya ZhE, Rozhinskaya LYa. Novye napravleniya v terapii osteoporoza – primenenie monoklonal'nyh chelovecheskih antitel k RANKL (Denosumab). Osteoporosis and Bone Diseases. 2011;14(2):23-26. (In Russ).] doi: 10.14341/osteo2011223-26</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Hoyer-Kuhn H, Netzer C, Koerber F, et al. Two years’ experience with denosumab for children with osteogenesis imperfecta type VI. Orphanet J Rare Dis. 2014;9:145 doi: 10.1186/s13023-014-0145-1</mixed-citation><mixed-citation xml:lang="en">Hoyer-Kuhn H, Netzer C, Koerber F, et al. Two years’ experience with denosumab for children with osteogenesis imperfecta type VI. Orphanet J Rare Dis. 2014;9:145 doi: 10.1186/s13023-014-0145-1</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Semler O, Netzer C, Hoyer-Kuhn H, Becker J, et al. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact. 2012;12(3):183–8</mixed-citation><mixed-citation xml:lang="en">Semler O, Netzer C, Hoyer-Kuhn H, Becker J, et al. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact. 2012;12(3):183–8</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Li F, Wang X, Niyibizi C. Bone marrow stromal cells contribute to bone formation following infusion into femoral cavities of a mouse model of osteogenesis imperfecta. Bone. 2010;47(3):546–55. doi: 10.1016/j.bone.2010.05.040</mixed-citation><mixed-citation xml:lang="en">Li F, Wang X, Niyibizi C. Bone marrow stromal cells contribute to bone formation following infusion into femoral cavities of a mouse model of osteogenesis imperfecta. Bone. 2010;47(3):546–55. doi: 10.1016/j.bone.2010.05.040</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Guillot PV, Abass O, Bassett JH, et al. Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice. Blood. 2008;111(3):1717–25. doi: 10.1182/blood-2007-08-105809</mixed-citation><mixed-citation xml:lang="en">Guillot PV, Abass O, Bassett JH, et al. Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice. Blood. 2008;111(3):1717–25. doi: 10.1182/blood-2007-08-105809</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Vanleene M, Saldanha Z, Cloyd KL, et al. Transplantation of human fetal blood stem cells in the osteogenesis imperfecta mouse leads to improvement in multiscale tissue properties. Blood. 2011;117(3):1053–60. doi: 10.1182/blood-2010-05-287565</mixed-citation><mixed-citation xml:lang="en">Vanleene M, Saldanha Z, Cloyd KL, et al. Transplantation of human fetal blood stem cells in the osteogenesis imperfecta mouse leads to improvement in multiscale tissue properties. Blood. 2011;117(3):1053–60. doi: 10.1182/blood-2010-05-287565</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
